UNSPSC 51281665: Sisomicin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula 2C19H37N5O7.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K14444371C, chemically known as o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-l-streptamine sulfate (2:5) (salt) but more generally known as sisomicin sulfate, which bears US NIH Compound Identifier 65334.

UNSPSC 51281665 Sisomicin sulfate is a Commodity code that does not align with the actual pharmaceutical and medical supply work being solicited by state and local governments under this code identifier. The recent opportunities tagged to this code show no purchases of sisomicin sulfate, an aminoglycoside antibiotic. Instead, the opportunities reflect procurement of generic pharmaceuticals, over-the-counter products, naloxone (an opioid antagonist), medical and first aid supplies for emergency response, and direct-to-manufacturer pharmacy benefit initiatives. This disconnect suggests either a data-tagging error in the source material or that sisomicin sulfate itself sees no recent state and local solicitation activity.

The geographic and issuing-body spread across the tagged opportunities spans state agencies (Minnesota Department of Administration via MMCAP cooperative purchasing for a multistate alliance including Oregon, and Texas Health and Human Services Commission), counties (Seminole County, Florida), and cities (Tampa, Florida). The most concrete recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a 5 percent bid discount sheltered for certified Small Local Business Enterprises (due March 13, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple states, with proposals due March 26, 2026. The Texas HHS RFI for direct-to-manufacturer prescriptions (posted April 3, 2026) signals state interest in alternative pharmacy supply models outside traditional pharmacy benefit manager arrangements. Pursuit of this code requires clarification of the actual procurement scope, as the code name and recent activity show minimal or no overlap.